The increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption - A nation-wide perspective in Sweden

Parkinsonism and Related Disorders

Volumn 9, Issue 5, 2003, Pages 271-276

  Askmark, Håkan ^a   Antonov, Karolina ^b   Aquilonius, Sten Magnus ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Apoteket AB   (Sweden)

Author keywords

Catechol O methyltransferase inhibitors; Dopamine agonists; Levodopa; Parkinson's disease; Pharmacoepidemiology

Indexed keywords

CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PRAMIPEXOLE; ROPINIROLE;

ARTICLE; DRUG COST; DRUG MARKETING; DRUG USE; HEALTH SURVEY; MEDICAL SPECIALIST; PARKINSON DISEASE; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; STATISTICS; SWEDEN;

CATECHOL O-METHYLTRANSFERASE; DOPAMINE AGENTS; ENZYME INHIBITORS; HUMANS; LEVODOPA; PARKINSON DISEASE; PHARMACOEPIDEMIOLOGY; PHYSICIAN'S PRACTICE PATTERNS; SWEDEN;

EID: 0038699004     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(02)00117-7     Document Type: Article

References (23)

1. Marsden C.D., Parkes J.D. Success and problems of long term levodopa theray in parkinson's disease. Lancet. 1:1977;345-349.
2. Olanow C.W. Oxidation reactions in parkinson's disease. Neurology. 40:(suppl. 3):1990;32-37.
3. Fahn S. Is levodopa toxic? Neurology. 47:1996;S184-S185.
4. Agid Y., Ahlskog E., Albanese A., Calne D., Chase T., De Yebanese J., et al. Levodopa in the treatment of parkinson's disease: a consensus meeting. Mov Disord. 14:1999;911-913.
5. Olanow C.W. A rationale for dopamine agonists as primary therapy in parkinson's disease. Can J Neurol Sci. 19:1992;108-112.
6. Olanow C.W., Jenner P., Brooks D. Dopamine agonists and neuroprotection in parkinson's disease. Ann Neurol. 44:(suppl. 1):1998;167-174.
7. Fischer P.A. Treatment strategies in parkinson's disease after a quarter century experiences with L-DOPA therapy. J Neurol Transm Suppl. 46:1995;381-399.
8. Uitti R.J., Ahlskog J.E. Comparative review of dopamine receptor agonists in parkinson's disease. CNS Drugs. 5:1996;369-388.
9. Oertel W.H., Quinn N.P. Parkinson's disease: drug therapy. Bailliers Clin Neurol. 6:1997;89-108.
10. Brooks D.J. Dopamine agonists: their role in the treatment of parkinson's disease. J Neurol Neurosurg Psychiatry. 68:2000;685-690.
11. Aquilonius S.M., Granat M., Hartvig P. Utilization of antiparkinson drugs in Norway, Sweden, Denmark and Finland 1975-1979. Acta Neurol Scand. 64:1981;47-53.
12. Aquilonius S.M., Hartvig P. A Swedish county with unexpectedly high utilization of anti-parkinson drugs. Acta Neurol Scand. 74:1986;379-382.
13. de Pedro-Cuesta J., Petersen I.J., Vassilopoulos D., Micheli F., Garcia I.A. Epidemiological assessment of levodopa use by populations. Acta Neurol Scand. 83:1991;328-335.
14. de Pedro-Cuesta J., Wermuth L., Abraira V., Stawiarz L. Levodopa use in Denmark: high levels in Greenland and the Faroe Islands. Acta Neurol Scand. 91:(2):1995;89-97.
15. Swedish drug statistics 2000. Apoteket AB, Stockholm; 2001.
16. ATC index with DDD's 2001. WHO Collaborating Centre for Drug Statistics Methodology. WHO, Oslo; 2000.
17. Miyasaki J.M., Martin W., Suchowersky O., Weiner W.J., Lang A.E. Practice parameter: initiation of treatment for parkinson's disease: an evidenced based review. Neurology. 58:2002;11-17.
18. de Rijk M.C., Tzourio C., Breteler M.M.B., Dartigues J.F., Amaducci L., Lopez-Pousa S., et al. Prevalence of parkinsonism and parkinson's disease in Europe: the Europarkinson collaborative study. European community concerted action on the epidemiology of parkinson's disease. J Neurol Neurosurg Psychiatry. 62:1997;10-15.
19. de Rijk M.C., Launer L.J., Berger K., Breteler M.M.B., Dartigues J.F., Baldereschi M., et al. Prevalence of parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurology. 54:(suppl. 5):2000;S21-S23.
20. Baldereschi M., DiCarlo A., Rocca W.A., Vanni P., Maggi S., Perisinotti E., et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher increase in men. Neurology. 55:2000;1358-1363. Italian longitudinal study on aging.
21. Clarke C.E., Speller J.M., Clarke J.A. Pramipexole versus bromocriptine for levodopa-induced complications in parkinson's disease. Cochrane Database Syst Rev. (3):2000;CD002259.
22. Clarke C.E., Deane K.H. Ropinirole versus bromocriptine for levodopa-induced complications in parkinson's disease (Cochrane review). Cochrane Database Syst Rev. 1:2001;CD001517.
23. Clarke C.E., Deane K.D. Cabergoline versus bromocriptine for levodopa-induced complications in parkinson's disease (Cochrane review). Cochrane Database Syst Rev. 1:2001;CD001519.